Randomized Controlled Trial of ProstAtak® Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

• Status: Active, not recruiting
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in patients undergoing active surveillance for localized prostate cancer. ProstAtak® involves the use of aglatimagene besadenovec (CAN-2409) to kill tumor cells and stimulate a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. ProstAtak® has been well tolerated in previous trials in patients with prostate cancer and other tumor types. Biochemical, pathologic and immune responses have been demonstrated in newly diagnosed and recurrent prostate cancer. The hypothesis is that ProstAtak can lead to improvement in the clinical outcome for patients with prostate cancer. Participants will be randomized to the ProstAtak® or control arm at a 2:1 ratio. Both arms receive standard of care active surveillance evaluations.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Advantagene, Inc.; Candel Therapeutics, Inc.
• Treatments: Acyclovir; Valacyclovir

Criteria

Inclusion Criteria include:

• Histologically confirmed adenocarcinoma of the prostate

• Patients choosing active surveillance

• Patients meeting definition of NCCN low risk, intermediate risk OR patients having only one NCCN high-risk feature

• NCCN Low Risk is defined as having all of the following: PSA < 10 ng/ml, Gleason ≤ 6, T1-T2a

• NCCN Intermediate Risk is defined as having at least one of the following and no high risk features: PSA 10-20 ng/ml, Gleason score =7, T2b-T2c

• High Risk with a single high risk feature is defined as having only one of the following: PSA>20 ng/ml, Gleason score 8-10, or T3a

• Excluded are those in the following risk groups: High risk with more than 1 high risk factor; Locally advanced/very high risk=T3b-T4; Metastatic: N1 or M1

• Patients must be planning and medically able to tolerate multiple transrectal ultrasound guided injections.

• ECOG Performance status 0-2

Exclusion Criteria include:

• Active liver disease, including known cirrhosis or active hepatitis

• Patients on systemic corticosteroids (>10 mg prednisone per day) or other immunosuppressive drugs

• Known HIV+ patients

• Regional lymph node involvement or distant metastases

• Other current malignancy (except squamous or basal cell skin cancers)

• Other serious co-morbid illness or compromised organ function that, in the opinion of the investigator, would interfere with treatment or follow up

• Prior treatment for prostate cancer except TURP. If prior TURP, patients must be deemed able to receive prostate biopsy and multiple intra-prostatic injections by the investigator

• Patients taking 5-alpha-reductase inhibitors (e.g. finasteride, dutasteride)

• Patients who had or plan to use ADT or have history of an orchiectomy.

• Patients who are planning to undergo radical treatment for prostate cancer within 12 months.

• Known sensitivity or allergic reactions to acyclovir or valacyclovir